Glut 1 deficiency syndrome trial announces negative results – Ataxia

Glut 1 deficiency syndrome trial announces negative results

Glut 1 deficiency syndrome trial announces negative results

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare genetic diseases has announced that its Phase 3 study of a potential therapy for Glucose transporter 1 deficiency syndrome (Glut1 DS) did not produce a positive result. Glut1 DS is a condition which results in seizures, developmental delay as well as ataxia. See Ataxia UK’s Medical Guidelines here

“We had previously observed significant improvements in individual cases of Glut1 DS with UX007 and so we are particularly disappointed by the results of the Glut1 DS study in a larger group of patients that did not demonstrate this same effect” said Emil Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.

Development of UX007 in Glut 1 DS will therefore unfortunately be discontinued, however it will continue to be investigated for other, similar disorders. For the full press release see here

Posted on 27/11/2018


Something went wrong. Please check your entries and try again.
fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Welcome to our new site! We hope you like it.
As it's brand new, there may be a few temporary glitches such as broken links - we are working on getting these all fixed ASAP. If you'd like to give us any feedback or let us know if something isn't quite right, please email
Scroll to Top